These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 17043629)

  • 21. Radioimmunotherapy of prostate cancer.
    Smith-Jones PM
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted alpha-therapy for control of micrometastatic prostate cancer.
    Li Y; Russell PJ; Allen BJ
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):459-68. PubMed ID: 15161444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted alpha therapy: part I.
    Elgqvist J
    Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
    Kotzerke J; Bunjes D; Scheinberg DA
    Bone Marrow Transplant; 2005 Dec; 36(12):1021-6. PubMed ID: 16247432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
    Zalutsky MR; Reardon DA; Pozzi OR; Vaidyanathan G; Bigner DD
    Nucl Med Biol; 2007 Oct; 34(7):779-85. PubMed ID: 17921029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioimmunotherapy and colorectal cancer.
    Koppe MJ; Bleichrodt RP; Oyen WJ; Boerman OC
    Br J Surg; 2005 Mar; 92(3):264-76. PubMed ID: 15739250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Status of radioimmunotherapy in the new millennium.
    Imam SK
    Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
    Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
    Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies for developing effective radioimmunotherapy for solid tumors.
    DeNardo GL; O'Donnell RT; Kroger LA; Richman CM; Goldstein DS; Shen S; DeNardo SJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3219s-3223s. PubMed ID: 10541367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
    Aghevlian S; Boyle AJ; Reilly RM
    Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted alpha-therapy: past, present, future?
    Brechbiel MW
    Dalton Trans; 2007 Nov; (43):4918-28. PubMed ID: 17992276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging trends for radioimmunotherapy in solid tumors.
    Jain M; Gupta S; Kaur S; Ponnusamy MP; Batra SK
    Cancer Biother Radiopharm; 2013 Nov; 28(9):639-50. PubMed ID: 23844555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioimmunotherapy with α-particle-emitting radionuclides.
    Seidl C
    Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
    Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monoclonal antibodies. General approach and radioimmunotherapy].
    Sousa O; Vieira E
    Acta Med Port; 1998 Apr; 11(4):337-47. PubMed ID: 9644845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.
    Martins CD; Kramer-Marek G; Oyen WJG
    Expert Opin Drug Deliv; 2018 Feb; 15(2):185-196. PubMed ID: 28893110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Systemic radiotherapy using monoclonal antibodies. Options and problems].
    Sautter-Bihl ML; Wannenmacher M; Bihl H
    Strahlenther Onkol; 1993 Jun; 169(6):358-65. PubMed ID: 8316939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
    Albrecht H; Denardo GL; Denardo SJ
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):304-13. PubMed ID: 17464275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.